

## **Literatur zu Aderhold - Neuroleptika minimieren**

**Vollständige Aufsätze können angefordert werden unter:**

**v.aderhold@gmx.de**

**Die Mortalitätsstudien online unter:** <http://psychrights.org/index.htm>

unter: „Scientific Research by Topic“,

dort die Artikel von Ray, Joukamaa, Montout, Henderson, Morgan, Straus.

Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, van Dyck CH, Charney DS, Innis RB, Laruelle M.(1998) Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. *Am J Psychiatry*. 1998 Jun;155(6):761-7.

Abi-Dargham A., Kegeles L, Zea-Ponce Y, et al (1999): Removal of endogenous Dopamine reveals elevation of D2 Receptors in Schizophrenia. *J Nuc Med* 40 (Suppl): 30P

Abi-Dargham, A., Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, Weiss R, Cooper TB, Mann JJ, Van Heertum RL, Gorman JM, Laruelle M.(2000): Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. *Proc Natl Acad Sci USA*. 97(14): 8104-9

Aderhold, V.; Alanen, Y.; Hess, G.; Hohn, P. (Hrsg) (2003): *Psychotherapie der Psychosen Integrative Behandlungsansätze aus Skandinavien, Gießen*

Alanen, Y.O. (2001). *Schizophrenie. Entstehung, Erscheinungsformen und die bedürfnisangepasste Behandlung*. Klett-Cotta, Stuttgart

Albus M, Hubmann W, Scherer J, Dreikorn B, Hecht S, Sobizack N, Mohr F.(2002): A prospective 2-year follow-up study of neurocognitive functioning in patients with first-episode schizophrenia. *Eur Arch Psychiatry Clin Neurosci*. 252(6):262-7.

Amering M. & Schmolke (2007): *Recovery. Das Ende der Unheilbarkeit*. Bonn (Psychiatrie Verlag)

Anil Yağcıoğlu AE, Kivircik Akdede BB, Turgut TI, Tümüklü M, Yazici MK, Alptekin K, Ertuğrul A, Jayathilake K, Göğüş A, Tunca Z, Meltzer HY.(2005): A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. *J Clin Psychiatry*. 2005 Jan;66(1):63-72.

Andreasen, N.C., Moser, D.J., O'Leary, H.S. & Ho, B.C.(2005). Longitudinal changes in neurocognition during the first decade of schizophrenia illness. *Schizophrenia Bulletin*, 31, 348.

Artaloytia JF, Arango C, Lahti A, Sanz J, Pascual A, Cubero P, Prieto D, Palomo T.(2006): Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. *Am J Psychiatry*. 163 (3):488-93.

Assaf M, Rivkin PR, Kuzu CH, Calhoun VD, Kraut MA, Groth KM, Yassa MA, Hart J, Pearlson GD.(2006): Abnormal object recall and anterior cingulate overactivation correlate with formal thought disorder in schizophrenia. *Biol. Psychiatry*. 59(5):452-9.

Azorin JM, Spiegel R, Remington G, Vanelle JM, Péré JJ, Giguere M, Bourdeix I.(2001): A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. *Am J Psychiatry*. 2001 Aug;158(8):1305-13.

Baker, D. (2004).: *Financing Drug Research: What are the issues?* Center for Economic and Policy Research, Washington

Baldessarini, R.J. & Tarsy, D. (1980). Dopamine and the pathophysiology of dyskinesia induced by antipsychotic drugs. *Annual review of neuroscience*, 3, 23-41.

Baldessarini R.J., Viguera A.C. (1995): Neuroleptic withdrawal in schizophrenic patients. *Arch. Gen. Psychiatry*. 1995 Mar;52(3):189-92.

Behl C, Rupprecht R, Skutella T, Holsboer F.(1995): Haloperidol-induced cell death--mechanism and protection with vitamin E in vitro. *Neuroreport*. 29;7(1):360-4.

Berridge KC, Robinson TE.(1998) What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? *Brain Res Brain Res Rev*. 1998 Dec;28(3):309-69.

Bockoven, J.S. & Solomon, H.C. (1975). Comparison of Two Five-Year Follow-Up Studies: 1947 to 1952 and 1967 to 1972. *American Journal of Psychiatry*, 132, 796-801.

Bola, J.R. (2006). Medication-free research in early episode schizophrenia: evidence of long-term harm? *Schizophrenia Bulletin*, 32, 288-96.

Bola JR, Lehtinen K, Aaltonen J, Rääköläinen V, Syvälahti E, Lehtinen V.(2006): Predicting medication-free treatment response in acute psychosis: cross-validation from the Finnish Need-Adapted Project. *J Nerv Ment Dis*. 194(10):732-9.

Bola, J.R., Mosher L.R.: At Issue: Predicting Drug-Free Treatment Response in Acute Psychosis from the Soteria Project. *Schizophrenia Bulletin* 28 (2002) 559-575

Bola JR, Mosher LR.(2003): Treatment of acute psychosis without neuroleptics: two-year outcomes from the Soteria project. In: *J Nerv Ment Dis.*, 191(4), S. 219-229

Bonelli RM, Hofmann P, Aschoff A, Niederwieser G, Heuberger C, Jirikowski G, Kapfhammer HP.(2005): The influence of psychotropic drugs on cerebral cell death: female neurovulnerability to antipsychotics. *Int Clin Psychopharmacol*. 20(3):145-9.

Bralet MC, Yon V, Loas G, Noisette C.(2000):[Cause of mortality in schizophrenic patients: prospective study of years of a cohort of 150 chronic schizophrenic patients][Article in French] *Encephale*. 26(6):32-41

Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D.(1997): Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. *Proc Natl Acad Sci USA*. 94(6):2569-74

Brown S, Inskip H, Barraclough B.(2000) Causes of the excess mortality of schizophrenia. *Br J Psychiatry*. 2000 Sep;177:212-7.

Buckley, P.: Identifying Schizophrenic Patients who Should not Receive Medication. *Schizophr. Bull*. 8 (1982) 429-432

Cahn W, Hulshoff Pol HE, Lems EB, van Haren NE, Schnack HG, van der Linden JA, Schothorst PF, van Engeland H, Kahn RS.(2002): Brain volume changes in first-episode schizophrenia: a 1-year follow-up study. *Arch. Gen. Psychiatry*. 59(11):1002-10.

Carpenter W.T. Jr.(1997): The risk of medication-free research. *Schizophr Bull*. 1997;23(1):11-8.

Carpenter, W.T. Jr, Buchanan, R.W., Kirkpatrick, B. & Breier, A.F.(1999). Diazepam treatment of early signs of exacerbation in schizophrenia. *American Journal of Psychiatry*, 156, 299-303.

Carpenter W.T., Heinrichs D.W., Wagman A.M.(1988): Deficit and nondeficit forms of schizophrenia: the concept. *Am J Psychiatry*. 145(5):578-83.

Carpenter, W.T., McGlashan, T.H., Strauss, J.S.: The Treatment of Acute Schizophrenia without Drugs: An Investigation of some Current Assumptions. *Am. J. Psychiatry* 134 (1977) 14-20

Ciampi, L. & Müller, C. (1976): *Lebensweg und Alter der Schizophrenen*. Berlin Heidelberg New York

Ciampi, L., Kupper, Z., Aebi, E. et al.. (1993): Das Pilot-Projekt „Soteria Bern“ zur Behandlung akut Schizophrener. II. Ergebnisse einer vergleichenden prospektiven Verlaufsstudie über 2 Jahre. *Nervenarzt* 64: 440-450

Cohn T, Prud'homme D, Streiner D, Kameh H, Remington G. (2004) Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. *Can J Psychiatry*. 49(11):753-60.

Colton CW, Manderscheid RW.(2006): Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. *Prev Chronic Dis*. 3(2):1-14

Correll CU, Frederickson AM, Kane JM, Manu P.(2006): Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. *J Clin Psychiatry*. 67(4):575-83.

Craig TK, Garety P, Power P, Rahaman N, Colbert S, Fornells-Ambrojo M, Dunn G.(2004). The Lambeth Early Onset (LEO) Team: randomised controlled trial of the effectiveness of specialised care for early psychosis. *BMJ*. 2004, 329(7474):1067.

Crumlish N, Whitty P, Kamali M, Clarke M, Browne S, McTigue O, Lane A, Kinsella A, Larkin C, O'Callaghan E.(2005): Early insight predicts depression and attempted suicide after 4 years in first-episode schizophrenia and schizophreniform disorder. *Acta Psychiatr Scand*. 112(6):449-55.

Cullberg, J.(2006): *Psychoses - An integrative perspective*, London, New York (Routledge)

Damsma G, Pfaus JG, Wenkstern D, Phillips AG, Fibiger HC.(1992) Sexual behavior increases dopamine transmission in the nucleus accumbens and striatum of male rats: comparison with novelty and locomotion. *Behav Neurosci*. 1992 Feb;106(1):181-91.

Dazzan P, Morgan KD, Orr K, Hutchinson G, Chitnis X, Suckling J, Fearon P, McGuire PK, Mallett RM, Jones PB, Leff J, Murray RM.(2005): Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: the AESOP study. *Neuropsychopharmacology*. 30(4):765-74.

de Haan L, Lavalaye J, Linszen D, Dingemans PM, Booij J.(2000): Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. *Am J Psychiatry*. 157(6):1019-20.

de Leon J, Armstrong SC, Cozza KL.(2006): Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. *Psychosomatics* 47(1):75-85.

Dorph-Petersen, K.A., Pierri, J.N., Perel, J.M., Sun, Z., Sampson, A.R. & Lewis, D.A. (2005). The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. *Neuropsychopharmacology*, 2005, 1649-1661.

Dose, M. (2002): Die schöne Welt der Neuen Neuroleptika – eine kritische Betrachtung. In: *Schizophrenie – Mitteilungsorgan der gfts*, 18: 36-55

Emsley R, Oosthuizen PP, Kidd M, Koen L, Niehaus DJ, Turner HJ. (2006): Remission in first-episode psychosis: predictor variables and symptom improvement patterns. *J Clin Psychiatry*. 67(11):1707-12.

Evans JR, Rodnick EH, Goldstein MJ, Judd LL. (1972): Premorbid adjustment, phenothiazine treatment, and remission in acute schizophrenics. *Arch Gen Psychiatry*. 27(4):486-90

Falloon IRH (2006): Antipsychotic Drugs: When and how to withdraw them? *Psychother Psychosom* 75: 133-138

Farberow, N., Ganzler, S., Cuttler, F. et al (1978): Status of Suicides in Veterans Administration Hospitals. Reports 2 4. Los Angeles, CA: Central Research Unit, V. A. Wadsworth Hospital Center.

Farde, L., Wiesel, F.A., Stone-Elander, S., Halldin, C., Nordstrom, A.L., Hall, H. & Sedvall, G. (1990). D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [<sup>11</sup>C]raclopride. *Archives of General Psychiatry*, 47, 213-219.

Fenton S.W., Blyler C.R., Heinssen R.K. (1997): Determinants of Medication Compliance in Schizophrenia: Empirical and Clinical Findings. *Schizophren. Bull.* 23, S. 637-651

Fenton, W.S., McGlashan T.H.: Sustained Remission in Drug-Free Schizophrenic Patients. *Am. J. Psychiatry* 144 (1987) 1306-1309

Finzen, A. (1988): *Der Patientensuizid*, Bonn 1988

Freeman, D., Freeman, J., & Garety, P. (2006): Overcoming Paranoid and Suspicious Thoughts. *Robinson Constable*

Fu, C.H., Suckling J., Williams S.C., Andrew C.M., Vythelingum G.N., McGuire P.K. (2005): Effects of psychotic state and task demand on prefrontal function in schizophrenia: an fMRI study of overt verbal fluency. *Am J Psychiatry*. 162(3):485-94.

Fuller-Torrey, E. (2002): The going rate on shrinks: Big Pharma and the buying of psychiatry. *American Prospect*, July 15 - online publication

Gaebel W, Jänner M, Frommann N, Pietzcker A, Köpcke W, Linden M, Müller P, Müller-Spahn F, Tegeler J. (2002): First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. *Schizophr Res*. 53(1-2):145-59.

Gardos G., Cole J.O., Tarsy D. (1978): Withdrawal syndromes associated with antipsychotic drugs. *Am J Psychiatry*. 1978 Nov;135(11):1321-4.

Garety PA, Craig TK, Dunn G, Fornells-Ambrojo M, Colbert S, Rahaman N, Read J, Power P. (2006): Specialised care for early psychosis: symptoms, social functioning and patient satisfaction: randomised controlled trial. *Br J Psychiatry*. 2006 Jan;188:37-45.

Gejman PV, Ram A, Gelernter J, Friedman E, Cao Q, Pickar D, Blum K, Noble EP, Kranzler HR, O'Malley S. (1994): No structural mutation in the dopamine D2 receptor gene in alcoholism or schizophrenia. Analysis using denaturing gradient gel electrophoresis. *JAMA*. 271(3):204-8.

Genç Y, Taner E, Candansayar S.(2007): Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study. *Adv Ther*.24(1):1-13.

Gilbert PL, Harris MJ, McAdams LA, Jeste DV.(1995): Neuroleptic withdrawal in schizophrenic patients. A review of the literature. *Arch Gen Psychiatry*. 52(3):173-88.

Glassman AH, Bigger JT.(2001): Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. *Am J Psychiatry*.158 (11):1774-82.

Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, Lamberti S, D'Agostino RB, Stroup TS, Davis S, Lieberman JA.(2005): A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. *Schizophr. Res*. 80(1):45-53.

Goldstein, M.J.: Premorbid Adjustment, Paranoid Status and Patterns of Response to Phenothiazine in Acute Schizophrenia. *Schizophr. Bull*. 1 (1970) 24-27

Gur RE, Cowell P, Turetsky BI, Gallacher F, Cannon T, Bilker W, Gur RC.(1998a): A follow-up magnetic resonance imaging study of schizophrenia. Relationship of neuroanatomical changes to clinical and neurobehavioral measures. *Arch. Gen. Psychiatry*.55(2):145-52.

Gur RE, Maany V, Mozley PD, Swanson C, Bilker W, Gur RC.(1998b): Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. *Am J Psychiatry*. 155(12):1711-7.

Gur RE, Turetsky BI, Cowell PE, Finkelman C, Maany V, Grossman RI, Arnold SE, Bilker WB, Gur RC.(2000): Temporolimbic volume reductions in schizophrenia. *Arch. Gen. Psychiatry*. 57(8):769-75.

Halim ND, Weickert CS, McClintock BW, Weinberger DR, Lipska BK.(2004): Effects of chronic haloperidol and clozapine treatment on neurogenesis in the adult rat hippocampus. *Neuropsychopharmacology*. 29(6):1063-9.

Harding, C.M., Brooks, G.W., Ashikaga, T., Strauss, J.S. & Breier, A.(1987). The Vermont longitudinal study of persons with severe mental illness, I: Methodology, study sample, and overall status 32 years later. *American Journal of Psychiatry*, 144, 718-26.

Harding, C.M., Brooks, G.W., Ashikaga, T., Strauss, J.S. & Breier, A.(1987). The Vermont longitudinal study of persons with severe mental illness, II: Long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia. *American Journal of Psychiatry*, 144, 727-735.

Harrington M., Lelliott P. , Paton C., Okocha R., Duffett R., Sensky, T.(2002) The results of a multi-centre audit of the prescribing of antipsychotic drugs for in-patients in the UK. *Psychiatric Bulletin* 26: 414-418

<http://pb.rcpsych.org/cgi/content/abstract/26/11/414Ha>

Harrow M, Jobe TH.(2007): Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications: a 15-year multifollow-up study. *J Nerv Ment Dis*. 195(5):406-14.

Healy D, Harris M, Tranter R, Gutting P, Austin R, Jones-Edwards G, Roberts AP.(2006): Lifetime suicide rates in treated schizophrenia: 1875-1924 and 1994-1998 cohorts compared. *Br J Psychiatry*. 2006 Mar;188:223-8.

Hegarty, J.D., Baldessarini, R.J., Tohen M. et al (1994): One hundred years of schizophrenia: a meta-analysis of the outcome literature. *Am J Psychiatry* 151, S.1409-1416

Heinz A.(2000): Dopaminhypothese der Schizophrenien. *Nervenarzt* 71(1):54-7

Heinz A, Braus DF, Romero B, Gallinat J, Puls I, Juckel G, Weinberger DR.(2004): Genetische und medikamentöse Einflüsse auf die Funktion des präfrontalen Kortex bei schizophrenen Patienten. *Nervenarzt*.75(9):845-56.

Heinz A, Knable MB, Coppola R, Gorey JG, Jones DW, Lee KS, Weinberger DR.(1998): Psychomotor slowing, negative symptoms and dopamine receptor availability—an IBZM SPECT study in neuroleptic-treated and drug-free schizophrenic patients. *Schizophr. Res.* 31(1):19-26.

Henderson DC, Nguyen DD, Copeland PM, Hayden DL, Borba CP, Louie PM, Freudenreich O, Evins AE, Cather C, Goff DC.(2005): Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. *J Clin Psychiatry*. 66(9):1116-21.

Henderson DC, Nguyen DD, Copeland PM, Hayden DL, Borba CP, Louie PM, Freudenreich O, Evins AE, Cather C, Goff DC.(2005): Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. *J Clin Psychiatry*. 2005 Sep;66(9):1116-21.

Hirvonen J, van Erp TG, Huttunen J, Aalto S, Nägren K, Huttunen M, Lönqvist J, Kaprio J, Cannon TD, Hietala J.(2006): Brain dopamine d1 receptors in twins discordant for schizophrenia. *Am J Psychiatry*. 163(10):1747-53.

Ho BC, Alicata D, Ward J, Moser DJ, O'Leary DS, Arndt S, Andreasen NC (2003): Untreated initial psychosis: relation to cognitive deficits and brain morphology in first-episode schizophrenia. *Am J Psychiatry* 160(1):142-8.

Ho BC, Andreasen NC, Nopoulos P, Arndt S, Magnotta V, Flaum M.(2003): Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. *Arch. Gen. Psychiatry*.60(6):585-94.

Hoff, A., DeLisi, L.E. & Maurizio, A.(2005a). Longitudinal neuropsychological findings of first-episode schizophrenia after ten years of illness. *Schizophrenia Bulletin*, 31, 326.

Hoff AL, Svetina C, Shields G, Stewart J, DeLisi LE.(2005b): Ten year longitudinal study of neuropsychological functioning subsequent to a first episode of schizophrenia. *Schizophr Res*.78(1):27-34.

Hogarty, G.E.; Ulrich, R.F. (1998): The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. In: *J Psychiatr Res*. 32(3-4), S. 243-250

Honer WG, Thornton AE, Chen EY, Chan RC, Wong JO, Bergmann A, Falkai P, Pomarol-Clotet E, McKenna PJ, Stip E, Williams R, MacEwan GW, Wasan K, Procyshyn R; Clozapine and Risperidone Enhancement (CARE) Study Group (2006) Clozapine alone versus clozapine and risperidone with refractory schizophrenia. *N Engl J Med*. 354(5):472-82.

Hulshoff Pol HE, Schnack HG, Mandl RC, van Haren NE, Koning H, Collins DL, Evans AC, Kahn RS.(2001): Focal gray matter density changes in schizophrenia. *Arch. Gen. Psychiatry.* 58(12):1118-25.

Inskip HM, Harris EC, Barraclough B.(1998): Lifetime risk of suicide for affective disorder, alcoholism and schizophrenia. *Br J Psychiatry.* 172:35-7.

Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, Taskinen MR, Groop L.(2001): Cardiovascular morbidity and mortality associated with the metabolic syndrome. *Diabetes Care.* 24(4):683-9.

Jarskog LF, Gilmore JH, Glantz LA, Gable KL, German TT, Tong RI, Lieberman JA.(2007): Caspase-3 activation in rat frontal cortex following treatment with typical and atypical antipsychotics. *Neuropsychopharmacology.* 32(1):95-102.

Jiko, I. (1997): Praktische Wege zur Gewaltvermeidung auf psychiatrischen Stationen, *Brückenschlag* 13: 146-150

Joseph KS, Blais L, Ernst P, Suissa S.(1996): Increased morbidity and mortality related to asthma among asthmatic patients who use major tranquillizers. *BMJ.* 312(7023):79-82.

Johnstone EC, Macmillan JF, Frith CD, Benn DK, Crow TJ.(1990): Further investigation of the predictors of outcome following first schizophrenic episodes. *Br J Psychiatry.* 157:182-9.

Josiassen RC, Joseph A, Kohegyi E, Stokes S, Dadvand M, Paing WW, Shaughnessy RA.(2005) Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. *Am J Psychiatry.* 2005 Jan;162(1):130-6.

Joukamaa M, Heliövaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. (2006): Schizophrenia, neuroleptic medication and mortality. In: *Br J Psychiatry.* 188(2), S. 122-127.

<http://ahrp.org/risks/antipsychotic/joukamaa2006.pdf>

Kane JM.(1996): Treatment-resistant schizophrenic patients. *J Clin Psychiatry.* 57 Suppl 9:35-40.

Kapur S, Mizrahi R, Li M.(2003): From dopamine to salience to psychosis--linking biology, pharmacology and phenomenology of psychosis. *Schizophr. Res.* 79(1):59-68.

Kapur S, Remington G, Jones C, Wilson A, DaSilva J, Houle S, Zipursky R.(1996) High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. *Am J Psychiatry.* 1996 Jul;153(7):948-50.

Kapur, S., Zipursky, R., Jones, C., Remington, G. & Houle, S. (2000). Relationship between Dopamine D 2 occupancy, clinical response and side effects: a double-blind PET study of first-episode Schizophrenia. *American Journal of Psychiatry,* 157, 514-520.

Kasai K., Shenton M.E., Salisbury D.F., Hirayasu Y., Onitsuka T., Spencer M.H., Yurgelun-Todd D.A., Kikinis R., Jolesz F.A., McCarley R.W.(2003): Progressive decrease of left Heschl gyrus and planum temporale gray matter volume in first-episode schizophrenia: a longitudinal magnetic resonance imaging study. *Arch. Gen. Psychiatry.* 60(8):766-75.

Keefe R.S., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M., Meltzer H.Y., Green M.F., Capuano G., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Davis C.E., Hsiao J.K., Lieberman J.A.; CATIE Investigators ; Neurocognitive

Working Group (2007): Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. *Arch. Gen. Psychiatry.* 64(6):633-47.

Keefe R.S., Seidman L.J., Christensen B.K., Hamer R.M., Sharma T., Sitskoorn M.M., Rock S.L., Woolson S., Tohen M., Tollefson G.D., Sanger T.M., Lieberman J.A.; HGDH Research Group (2006): Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. *Biol. Psychiatry.* 59(2):97-105.

Kelley JJ, Gao XM, Tamminga CA, Roberts RC.(1997): The effect of chronic haloperidol treatment on dendritic spines in the rat striatum. *Exp. Neurol.* 146(2):471-8.

Klaassen M.C., Nieman D.H., Becker H.E., Linszen D.H.(2006): Is there any point in detecting high risk factors prior to a first psychosis?[Article in Dutch] *Tijdschr Psychiatr.* 48(6):467-76.

Knable MB, Heinz A, Raedler T, Weinberger DR.(1997): Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels. *Psychiatry Res.* 75(2):91-101.

Kopala LC, Good KP, Honer WG.(1997): Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone. *J Clin Psychopharmacol.* 1997 Aug;17(4):308-13.

Kuipers E, Holloway F, Rabe-Hesketh S, Tennakoon L; Croydon Outreach and Assertive Support Team (COAST).(2004) An RCT of early intervention in psychosis: Croydon Outreach and Assertive Support Team (COAST). *Soc Psychiatry Psychiatr Epidemiol.* 39(5):358-63.

Laakso, A., Vilkmann, H., Alakare, B., Haaparanta, M., Bergman, J., Solin, O., Peurasaari, J., Rakkolainen, V., Syvalahti, E. & Hietala J.(2000). Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography. *American Journal of Psychiatry*, 157, 269-271.

Larsen TK, Melle I, Auestad B, Friis S, Haahr U, Johannessen JO, Opjordsmoen S, Rund BR, Simonsen E, Vaglum P, McGlashan T.(2006) Early detection of first-episode psychosis: the effect on 1-year outcome. *Schizophr Bull.*32 (4):758-64.

Laruelle M.(2000) The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. *Brain Res. Brain Res. Rev.* 31(2-3):371-84.

Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB.(1996) Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. *Proc Natl Acad Sci U S A.* 1996 Aug 20;93(17):9235-40.

Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R. (1999): Increased dopamine transmission in schizophrenia: relationship to illness phases. *Biol Psychiatry.* 46(1):56-72

Laruelle, M. & Abi-Dargham, A.(2000). Dopamine in the history of the schizophrenic brain: Recent contribution of brain-imaging studies. *Dialogues in Clinical Neuroscience*, 2, 359-372.

Lehmann, P. (1996): *Schöne neue Psychiatrie*, Berlin, Bd 1, (S. 57-87 und 109-115)



Lehmann, P. (2002): Behandlungsergebnis Selbsttötung. Suizidalität als mögliche Wirkung psychiatrischer Psychopharmaka. *Psychologie & Gesellschaftskritik*, 26(4): 99 – 111  
<http://www.antipsychiatrieverlag.de/artikel/gesundheit/suizid.htm>

Lehmann, P & Stastny P. (Hrsg.) (2007): *Statt Psychiatrie 2*, Berlin Antipsychiatrieverlag

Lehtinen V.; Aaltonen, J.; Koffert, T. u.a. (2000): Two-year outcome in first episode psychosis treated according to an integrated model. Is immediate neuroleptisation always needed? In: *European Psychiatry* 15, S.312-320

Lidow MS, Elsworth JD, Goldman-Rakic PS.(1997): Down-regulation of the D1 and D5 dopamine receptors in the primate prefrontal cortex by chronic treatment with antipsychotic drugs. *J. Pharmacol. Exp. Ther.* 281(1):597-603.

Lidow MS, Goldman-Rakic PS.(1994): A common action of clozapine, haloperidol, and remoxipride on D1- and D2-dopaminergic receptors in the primate cerebral cortex. *Proc. Natl. Acad. Sci. U.S.A.* 91(10):4353-6.

Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (2005a): Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *N Engl J Med.* 2005a, 353(12):1209-23.  
<http://content.nejm.org/cgi/reprint/353/12/1209.pdf?ijkey=jxORqp80h5n/k&keytype=ref&siteid=nejm>

Lieberman, J.A., Tollefson, G.D., Charles, C., Zipursky, R., Sharma, T., Kahn, R.S., Keefe R.S., Green A.I., Gur, R.E., McEvoy, J., Perkins, D., Hamer, R.M., Gu, H., Tohen, M.& HGDH Study Group (2005b): Antipsychotic drug effects on brain morphology in first-episode psychosis. *Archives of General Psychiatry*, 62(4): 361-370

Lindström LH, Gefvert O, Hagberg G, Lundberg T, Bergström M, Hartvig P, Långström B.(1999): Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. *Biol Psychiatry.* 1999 Sep 1;46(5):681-8.

Madsen A.L., Karle A, Rubin P, Cortsen M, Andersen HS, Hemmingsen R.(1999): Progressive atrophy of the frontal lobes in first-episode schizophrenia: interaction with clinical course and neuroleptic treatment. *Acta Psychiatr Scand.*100(5):367-74.

Madsen A.L., Keidling N, Karle A, Esbjerg S, Hemmingsen R.(1998): Neuroleptics in progressive structural brain abnormalities in psychiatric illness. *Lancet.* 352(9130):784-5.

Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Kane JM, Lieberman JA, Schooler NR, Covell N, Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, Pi-Sunyer X, Bigger JT Jr, Friedman A, Kleinberg D, Yevich SJ, Davis B, Shon S.(2004): Physical health monitoring of patients with schizophrenia. *Am J Psychiatry.* 161(8):1334-49.

Marder, S., van Kammen, D.P., Docherty, J.P., Rayner, J., Bunney, W.E.: Predicting Drug-Free Improvement in Schizophrenic Psychosis. *Arch. Gen. Psychiatry* 36 (1979) 1080-1085

Marshall M, Rathbone J. (2006). Early intervention for psychosis. *Cochrane Database Syst Rev.* 2006 Oct 18;(4):CD004718.

Martinot, J.L., Peron-Magnan, P., Huret, J.D., Mazoyer, B., Baron, J.C., Boulenger, J.P., Loc'h, C., Maziere, B., Caillard, V., Loo, H., et al.(1990): Striatal D2 dopaminergic receptors assessed

with positron emission tomography and [76Br]bromospiperone in untreated schizophrenic patients. *Am J Psychiatry*.147(1),S. 44-50.

Mathalon DH, Sullivan EV, Lim KO, Pfefferbaum A.(2001): Progressive brain volume changes and the clinical course of schizophrenia in men: a longitudinal magnetic resonance imaging study. *Arch. Gen. Psychiatry*. 58(2):148-57.

Matthews, S.M., Roper, M.T., Mosher, L.R., Menn, A.Z.,: (1979) A Non-Neuroleptic Treatment for Schizophrenia: Analysis of the Two-Year Postdischarge Risk of Relapse., in: *Schizophrenia Bulletin* 5: 322-333

McEvoy, J.P., Hogarty, G.E., Steingard, S. (1991). Optimal Dose of Neuroleptic in Acute Schizophrenia. *Archives of General. Psychiatry*, 48, 739-745.

McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T, Lieberman JA.(2005): Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. *Schizophr. Res.* 80(1):19-32.

McGlashan, T.H.(1988). A selective review of recent North American long-term follow up studies of schizophrenia. *Schizophrenia Bulletin*, 14, 515-542.

McGlashan TH & Fenton WS.(1993). Subtype progression and pathophysiologic deterioration in early schizophrenia. *Schizophrenia Bulletin*, 19, 71-84.

McGlashan TH.(2006a): At issue: is natural selection rendering schizophrenia less severe? *Schizophr Bull.* 2006 Jul;32(3):428-9.

McGlashan TH.(2006b): Is active psychosis neurotoxic? *Schizophr Bull.* 2006 Oct;32(4):609-13. Epub 2006 Aug 16.

McGorry PD, Chanen A, McCarthy E, Van Riel R, McKenzie D, Singh BS.(2001) Posttraumatic stress disorder following recent-onset psychosis. An unrecognized postpsychotic syndrome. *J Nerv Ment Dis* 179(5):253-8.

Meador-Woodruff JH, Haroutunian V, Powchik P, Davidson M, Davis KL, Watson SJ.(1997): Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex. Focal abnormalities in orbitofrontal cortex in schizophrenia. *Arch Gen Psychiatry*. 54(12):1089-95.

Meltzer HY.(1998): Suicide in schizophrenia: risk factors and clozapine treatment. *J Clin Psychiatry*. 59 Suppl 3:15-20.

Menon V, Anagnoson RT, Mathalon DH, Glover GH, Pfefferbaum A. (2001): Functional neuroanatomy of auditory working memory in schizophrenia: relation to positive and negative symptoms. *Neuroimage*.13(3):433-46.

Meredith GE, Switzer RC, Napier TC.(2004): Short-term, D2 receptor blockade induces synaptic degeneration, reduces levels of tyrosine hydroxylase and brain-derived neurotrophic factor, and enhances D2-mediated firing in the ventral pallidum. *Brain Res.* 995(1):14-22.

Meyer JM, Nasrallah HA, McEvoy JP, Goff DC, Davis SM, Chakos M, Patel JK, Keefe RS, Stroup TS, Lieberman JA.(2005): The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. *Schizophr. Res.* 80(1):9-18.

Milev, P., Ho, B.C., Arndt, S. & Andreasen, N.C. (2005). Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. *American Journal of Psychiatry*, 162, 495-506.

Möller HJ.(1995): The negative component in schizophrenia. *Acta Psychiatr Scand Suppl.* 388:11-4.

Morrison AP, French P, Walford L, Lewis SW, Kilcommons A, Green J, Parker S, Bentall RP.(2004): Cognitive therapy for the prevention of psychosis in people at ultra-high risk:randomised controlled trial. *Br J Psychiatry.* 2004 Oct;185:291-7.

Montout, C., Casadebaig, F., Lagnaoui, R., et al (2002). Neuroleptics and mortality in schizophrenia: prospective analysis of deaths in a French cohort of schizophrenic patients. *Schizophrenia Research*, 57, 147-156.

Morgan MG, Scully PJ, Youssef HA, Kinsella A, Owens JM, Waddington JL.(2003) Prospective analysis of premature mortality in schizophrenia in relation to health service engagement: a 7.5-year study within an epidemiologically complete, homogeneous population in rural Ireland. *Psychiatry Res.* 117(2):127-35.

Mortensen PB, Juel K.(1993): Mortality and causes of death in first admitted schizophrenic patients. *Br J Psychiatry.* 163:183-9.

National Institute for Clinical Excellence (2002): Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. (Technology Appraisal Guidance, No. 43). London: National Institute for Clinical Excellence.

Newcomer JW. (2005): Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. *CNS Drugs.* 2005;19 Suppl 1:1-93.

Ninan I, Kulkarni SK.(1998): Partial agonistic action of clozapine at dopamine D2 receptors in dopamine depleted animals. *Psychopharmacology (Berl.).*135(3):311-7.

Noh JS, Kang HJ, Kim EY, Sohn S, Chung YK, Kim SU, Gwag BJ.(2000): Haloperidol-induced neuronal apoptosis: role of p38 and c-Jun-NH(2)-terminal protein kinase. *J. Neurochem.*75(6):2327-34.

Nordstrom, A.L., Farde, L., Eriksson, L. & Halldin C. (1995). No elevated D2 dopamine receptors in neuroleptic-naive schizophrenic patients revealed by positron emission tomography and [<sup>11</sup>C]N-methylspiperone. *Psychiatry Research*, 61, 67-83.

O'Donnell P, Grace AA.(1998): Dysfunctions in multiple interrelated systems as the neurobiological bases of schizophrenic symptom clusters. *Schizophr Bull.* 24(2):267-83.

Ösby U, Correia N, Brandt L, Ekblom A, Sparén P. (2000). Mortality and causes of death in schizophrenia in Stockholm county, Sweden. *Schizophr Res.* 45(1-2):21-8.

Ösby, U., Nestor, C., Brandt, L., Ekblom, A., Sparén, P.(2000): Time trends in schizophrenia mortality in Stockholm County, Sweden: cohort study, *British Medical Journal* 321:483-484

Oosthuizen P, Emsley RA, Turner J, Keyter N.(2001): Determining the optimal dose of haloperidol in first-episode psychosis.*J Psychopharmacol.* 2001 Dec;15(4):251-5.

Oosthuizen P, Emsley R, Jadri Turner H, Keyter N.(2004): A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis.

Int J Neuropsychopharmacol. 2004 Jun;7(2):125-31.

Paton C, Whittington C, Barnes TR.(2007): Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: a meta-analysis. J Clin Psychopharmacol. 2007 Apr;27(2):198-204.

Peralta V, Cuesta MJ, Martinez-Larrea A, Serrano JF.(2000): Differentiating primary from secondary negative symptoms in schizophrenia: a study of neuroleptic-naive patients before and after treatment. Am J Psychiatry. 157(9):1461-6

Perlstein WM, Carter CS, Noll DC, Cohen JD.(2001): Relation of prefrontal cortex dysfunction to working memory and symptoms in schizophrenia. Am J Psychiatry.158(7):1105-13.

Pfaus JG, Damsma G, Nomikos GG, Wenkstern DG, Blaha CD, Phillips AG, Fibiger HC.(1990): Sexual behavior enhances central dopamine transmission in the male rat. Brain Res. 1990 Oct 22;530(2):345-8.

Räkköläinen, V., Vuorio, K., Syvälahti, E. et al. (1997): Observations of comprehensive psychotherapeutic treatment of new schizophrenic patients without neuroleptic drugs in Kupittaa hospital 1989-1992. Paper 11. ISPS-Symposium, Washington D.C.

Rappaport M., Hopkins, H.K., Hall, K., Bellaza T., Silverman J.(1978): Are There Schizophrenics for Whom Drugs May be Unnecessary or Contraindicated? Int. Pharmacopsychiatry 13:100-111

Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT.(2001): Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry. 58(12):1161-7.  
Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT.(2001): Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry. 58(12):1161-7.

Report House of Commons Influence Pharmaceutical Industry 2004  
<http://www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/42/4202.htm>

Roberts RC, Gaither LA, Gao XM, Kashyap SM, Tamminga CA.(1995): Ultrastructural correlates of haloperidol-induced oral dyskinesias in rat striatum. Synapse. 20(3):234-43.

Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RS, Swartz M, Perkins DO, Hsiao JK, Lieberman J; CATIE Study Investigators (2006): Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 163(12):2080-9.

Royal College of Psychiatrists (1997): The Association Between Antipsychotic Drugs and Sudden Death. Report of the Working Group of the Royal College of Psychiatrists' Psychopharmacology Sub-Group. Council Report CR 57. London

Royal College of Psychiatrists (2006): Consensus statement on high-dose antipsychotic medication. Council Report CR138, London

Salamone JD, Cousins MS, Snyder BJ.(1997): Behavioral functions of nucleus accumbens dopamine: empirical and conceptual problems with the anhedonia hypothesis. Neurosci Biobehav Rev. 1997 May;21(3):341-59.

Saugstad LF, Odegård O.(1979): Mortality in psychiatric hospitals in Norway 1950-1974. *Acta Psychiatr Scand.* 59(4):431-47.

Scherk H, Falkai P.(2004) Veränderungen der Hirnstruktur durch neuroleptische Medikation *Nervenarzt.* 75(11):1112-7.

Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, McGorry PD, van Hove I, Eerdeken M, Swyzen W, De Smedt G; Early Psychosis Global Working Group.(2005) Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. *Am J Psychiatry.* 2005 May;162(5):947-53.

Seeman P.(1987):Dopamine receptors and the dopamine hypothesis of schizophrenia. *Synapse.* 1(2):133-52.

Seikkula, J., Aaltonen, J., Alakare, B., Haarakangas, K. (2006). Five-years experiences of first-episode nonaffective psychosis in open-dialogue approach: Treatment principles, follow-up outcomes, and two case studies. *Psychotherapy and Research*, 16, 214-228.

Seikkula, J. & Arnkil, T.E. (2007): *Dialoge im Netzwerk*, Neumünster (Paranus Verlag)

Selemon LD, Kleinman JE, Herman MM, Goldman-Rakic PS.(2002): Smaller frontal gray matter volume in postmortem schizophrenic brains. *Am J Psychiatry.* (12):1983-91.

Schäfer, I., Lambert, M., Naber, D.(2004): Atypische Antipsychotika bei therapieresistenter Schizophrenie, In: *Nervenarzt* 75(1), S. 79-91

Schooler, N.R., Goldberg, S.C., Boothe, H., and Cole, J.O.(1967): One year after discharge: Community adjustment of Schizophrenic Patients. *American Journal of Psychiatry* 123: 986-995

Schröder J, Silvestri S, Bubeck B, Karr M, Demisch S, Scherrer S, Geider FJ, Sauer H.(1998): D2 dopamine receptor up-regulation, treatment response, neurological soft signs, and extrapyramidal side effects in schizophrenia: a follow-up study with 123I-iodobenzamide single photon emission computed tomography in the drug-naïve state and after neuroleptic treatment. *Biol. Psychiatry.* 1;43(9):660-5.

Schwab, M., Marx, C., Zanger, U.M., Eichelbaum, M.(2002): Pharnakogenetig der Cytochrom P 450-Enzyme. *Dt Ärzteblatt* 99(8) A:497-504

Schooler, N.R., Goldberg, S.C., Boothe, H., and Cole, J.O.: One year after discharge: Community adjustment of Schizophrenic Patients. *American Journal of Psychiatrie* 123 (1967) 986-995

Shiloh R, Zemishlany Z, Aizenberg D, Radwan M, Schwartz B, Dorfman-Etrog P, Modai I, Khaikin M, Weizman A.(1998): Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. *Br J Psychiatry.* 171:569-73.

Silverman, J.: *Altered States of Consciousness: Positive and Negative Outcomes.* *J. Altered States of consciousness* 2 (1975/76) 295-317

Silvestri S, Seeman MV, Negrete JC, Houle S, Shammi CM, Remington GJ, Kapur S, Zipursky RB, Wilson AA, Christensen BK, Seeman P.(2000): Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. *Psychopharmacology (Berl.).* 152(2):174-80.

- Simpson GM, Mahmoud RA, Lasser RA, Kujawa M, Bossie CA, Turkoz I, Rodriguez S, Gharabawi GM.(2006) A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. *J Clin Psychiatry*. 2006 Aug;67(8):1194-203.
- Stahl SM.(2001): "Hit-and-run" actions at dopamine receptors, part 1: Mechanism of action of atypical antipsychotics. *J Clin Psychiatry*. 62(9):670-1.
- Straus SM, Bleumink GS, Dieleman JP, van der Lei J, 't Jong GW, Kingma JH, Sturkenboom MC, Stricker BH. (2004): Antipsychotics and the risk of sudden cardiac death. *Arch. Intern. Med*. 164(12):1293-7.
- Thomassen R, Vandenbroucke JP, Rosendaal FR.(2001): Antipsychotic medication and venous thrombosis. *Br J Psychiatry*. 179:63-6.
- Tiihonen J, Walhbeck K, Lönnqvist J, Klaukka T, Ioannidis JP, Volavka J, Haukka J.(2006): Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. *BMJ*. 333(7561):224.
- Tollefson GD, Sanger TM.(1997): Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. *Am J Psychiatry*. 154(4):466-74.
- Tranter R, Healy D.(1998): Neuroleptic discontinuation syndromes. *J Psychopharmacol*. 12(4):401-6.
- Ukai W, Ozawa H, Tateno M, Hashimoto E, Saito T.(2004): Neurotoxic potential of haloperidol in comparison with risperidone: implication of Akt-mediated signal changes by haloperidol. *J Neural Transm*. 111(6):667-81.
- van Os J, Hanssen M, Bijl RV, Vollebergh W.(2001): Prevalence of psychotic disorder and community level of psychotic symptoms: an urban-rural comparison. *Arch Gen Psychiatry*. 2001 Jul;58(7):663-8.
- Vaillant, G.E.: The Prediction of Recovery in Schizophrenia. *Journal of Nervous and Mental Disease* 135 (1962) 534-543
- Viguera AC, Baldessarini RJ, Hegarty JD, van Kammen DP, Tohen M.(1997): Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. *Arch. Gen. Psychiatry*. 54(1):49-55.
- Waddington JL, Youssef HA, Kinsella A.(1998):Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study.
- Walker AM, Lanza LL, Arellano F, Rothman KJ.(1997): Mortality in current and former users of clozapine. *Epidemiology*. 8(6):671-7.
- Wang HD, Dunnavant FD, Jarman T, Deutch AY.(2004): Effects of antipsychotic drugs on neurogenesis in the forebrain of the adult rat. *Neuropsychopharmacology*. 29(7):1230-8.
- Weinberger DR.(1987): Implications of normal brain development for the pathogenesis of schizophrenia. *Arch. Gen. Psychiatry*. 44(7):660-9.
- Weiser M, Knobler H, Lubin G, Nahon D, Kravitz E, Caspi A, Noy S, Knobler HY, Davidson M.(2004): Body mass index and future schizophrenia in Israeli male adolescents. *J Clin Psychiatry*. 65(11):1546-9.

Wenkstern D, Pfaus JG, Fibiger HC.(1993): Dopamine transmission increases in the nucleus accumbens of male rats during their first exposure to sexually receptive female rats. *Brain Res.* 1993 Jul 30;618(1):41-6.

Witchel HJ, Hancox JC, Nutt DJ.(2003): Psychotropic drugs, cardiac arrhythmia, and sudden death. *J Clin Psychopharmacol.*23(1):58-77.

Wyatt RJ. Neuroleptics and the natural course of schizophrenia. *Schizophrenia Bulletin* 1991;17(2):325-351.

Young M.A., Meltzer H.Y.: The Relationship of Demographic, Clinical, and Outcome Variables to Neuroleptic Treatment Requirements. *Schizophr. Bull.* 6 (1980) 88-101

Yung AR, Phillips LJ, Yuen HP, Francey SM, McFarlane CA, Hallgren M, McGorry PD.(2003): Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. *Schizophr Res.* 60(1):21-32.

Zarate CA Jr, Patel J.(2001): Sudden cardiac death and antipsychotic drugs: do we know enough? *Arch Gen Psychiatry.* 58(12):1168-71.